Hyundai Bio FY 2025 Annual Report
Beta

Filed: March 30, 2026· period ending December 31, 2025DART

Hyundai Bio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 30, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Hyundai Bio FY 2025 Annual Report Analysis

Business Overview

• Core revenue from bio cosmetics and anti-hair loss products, 2025 sales KRW 3.52B, 96% domestic market share
• New launch of cosmetic line 'Dr.BRID C' with completed domestic online market test and US Amazon release in FY2025

Management Discussion & Analysis

• Revenue KRW 3.52B (-76.6% YoY), operating loss KRW 18.16B (turn from KRW 0.83B profit), net loss KRW 22.13B (up from KRW 6.93B loss)
• Revenue decline driven by absence of previous technology licensing sales of KRW 9.1B, plus soaring clinical trial R&D expenses

Risk Factors

• Referred to financial risk management details in consolidated financial statements note 34
• No explicit quantitative foreign exchange exposure or sensitivity disclosed

Hyundai Bio FY 2025 Key Financial Metrics
DART

Total Assets

KRW 130.7B

▲ +93.1% YoY

Operating Cash Flow

-KRW 17.0B

▼ -855.4% YoY

Source: KIFRS consolidated financial data from Hyundai Bio annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding